Primary Treatment: Niraparib · No Placebo Group · Phase 2
Dostarlimab and Niraparib treatmentExperimental Group · 2 Interventions: Dostarlimab, Niraparib · Intervention Types: Drug, Drug
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2
Screening: ~3 weeks
Reporting: up to 24 months
Closest Location: Moffitt Cancer Center · Tampa, FL
2009First Recorded Clinical Trial
1 TrialsResearching Penile Carcinoma
222 CompletedClinical Trials
Who is running the clinical trial?
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
486 Previous Clinical Trials
123,377 Total Patients Enrolled
4,621 Previous Clinical Trials
7,937,058 Total Patients Enrolled
Jad Chahoud, MD, MPHPrincipal InvestigatorMoffitt Cancer Center
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have a life expectancy of at least 12 weeks.
Participants who have progressed or had tolerance problems to no more than one prior line of therapy in the locally advanced setting or post platinum-based chemotherapy, including in a neoadjuvant or adjuvant setting or in combination with radiation therapy.
You must give written, informed consent to participate in the study and follow the study procedures.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.